Bio-Techne Corp

2 articles

Merck to Acquire US-Based Life Sciences Firm Bio-Techne for $11.3 Billion

Merck KGaA has entered a definitive agreement to acquire Bio-Techne Corp for $73 per share in cash, totaling approximately $11.3 billion. The transaction offers a 36% premium over Bio-Techne's recent

chemweek · 2026-06-26 02:22

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

Merck KGaA has agreed to acquire Bio-Techne Corp for $11.3 billion to expand its life-science research capabilities. The deal includes research reagents, proteins, and antibodies, funded via cash and

reuters · 2026-06-25 03:09